# Paul B. Chapman

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/paul-b-chapman/

## Facts

| Field | Value |
| --- | --- |
| Citations | 44,174 |
| Field | Melanoma and MAPK Pathways |
| h-index | 74 |
| i10-index | 201 |
| Last Known Institution | Memorial Sloan Kettering Cancer Center |
| OpenAlex ID | https://openalex.org/A5083883593 |
| ORCID iD | https://orcid.org/0000-0003-1618-0811 |
| Works | 514 |

## Researcher papers

- [<i>RAS</i> Mutations in Cutaneous Squamous-Cell Carcinomas in Patients Treated with BRAF Inhibitors](https://scholariq.org/papers/i-ras-i-mutations-in-cutaneous-squamous-cell-carcinomas-in-patients-treated-with/)
- [The RAF inhibitor PLX4032 inhibits ERK signaling and tumor cell proliferation in a V600E BRAF-selective manner](https://scholariq.org/papers/the-raf-inhibitor-plx4032-inhibits-erk-signaling-and-tumor-cell-proliferation-in/)
- [Loss of NF1 in Cutaneous Melanoma Is Associated with RAS Activation and MEK Dependence](https://scholariq.org/papers/loss-of-nf1-in-cutaneous-melanoma-is-associated-with-ras-activation-and-mek/)

## Researcher topics

- [Melanoma and MAPK Pathways](https://scholariq.org/topics/melanoma-and-mapk-pathways/)
- [Cutaneous Melanoma Detection and Management](https://scholariq.org/topics/cutaneous-melanoma-detection-and-management/)
- [Immunotherapy and Immune Responses](https://scholariq.org/topics/immunotherapy-and-immune-responses/)
- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)
- [CAR-T cell therapy research](https://scholariq.org/topics/car-t-cell-therapy-research/)

## Researcher university

- [Memorial Sloan Kettering Cancer Center](https://scholariq.org/institutions/memorial-sloan-kettering-cancer-center/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.